Foundry Partners LLC Trims Stock Position in Evolent Health, Inc. (NYSE:EVH)

Foundry Partners LLC decreased its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 39.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 215,325 shares of the technology company's stock after selling 139,773 shares during the period. Foundry Partners LLC owned 0.18% of Evolent Health worth $2,422,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of EVH. Salem Investment Counselors Inc. boosted its position in Evolent Health by 53.0% during the 4th quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company's stock valued at $3,939,000 after acquiring an additional 121,369 shares in the last quarter. Nordea Investment Management AB grew its stake in Evolent Health by 7.0% in the fourth quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company's stock valued at $1,469,000 after purchasing an additional 8,552 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in Evolent Health by 90.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company's stock worth $9,036,000 after purchasing an additional 380,790 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Evolent Health by 40.8% during the third quarter. Franklin Resources Inc. now owns 909,776 shares of the technology company's stock valued at $24,682,000 after buying an additional 263,815 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Evolent Health by 181.3% in the 3rd quarter. Barclays PLC now owns 273,776 shares of the technology company's stock valued at $7,742,000 after buying an additional 176,445 shares in the last quarter.

Insider Transactions at Evolent Health

In other Evolent Health news, Director Diane Holder purchased 2,735 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were purchased at an average cost of $9.33 per share, for a total transaction of $25,517.55. Following the completion of the transaction, the director now owns 70,584 shares of the company's stock, valued at $658,548.72. The trade was a 4.03 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brendan B. Springstubb acquired 5,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was acquired at an average price of $8.75 per share, with a total value of $43,750.00. Following the acquisition, the director now owns 11,842 shares in the company, valued at $103,617.50. The trade was a 73.08 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 74,000 shares of company stock valued at $666,315 in the last three months. 1.60% of the stock is currently owned by company insiders.

Evolent Health Stock Performance

NYSE EVH traded down $0.04 during mid-day trading on Thursday, reaching $9.96. 1,255,939 shares of the stock were exchanged, compared to its average volume of 2,265,673. The company has a market capitalization of $1.16 billion, a P/E ratio of -12.19 and a beta of 1.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The business's 50 day moving average is $9.72 and its 200-day moving average is $14.11. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last posted its earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. On average, equities research analysts forecast that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EVH. Truist Financial decreased their target price on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday. JPMorgan Chase & Co. lowered their price objective on Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research report on Monday, March 10th. Oppenheimer reduced their target price on Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 24th. Stephens lowered their price target on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a report on Tuesday, January 21st. Finally, Canaccord Genuity Group cut their price objective on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $17.64.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.